Elliot Tapper

One week ago, I arrived Las Vegas after fortunately securing one of the limited travel awards to attend the @AASLDtweets Emerging Topic Conference. I am still in awe of the top notch organization, the brilliant speakers and subject experts, including @ebtapper and @AlkhouriNaim, the quality of the sessions, and new connections established. As the @AASLDPresident, @saulkarpen noted, and has continued to resonate with me: 💉Only 2% of children ≥12 receive GLP-1 RAs 🩺 MASLD risk rises 4–5x among kids with parental obesity These are powerful reminders of the growing, intergenerational burden of liver disease, and how experiences like this, which foster collaboration, innovation, research, and education, remain central to advancing hepatology. Looking forward to maximizing the AASLD Programming at the @DDWMeeting in Chicago and in November, The Liver Meeting in Denver. Grateful for the learning and conversations, to @onebklynhealth and @OBHBrookdaleIM for the continued support and mentorship. #MASLD #MASH #Hepatology #AASLD #Hepatology #LiverDisease #DigitalHealth #CholestaticLiverDisease #PSC #PBC #ABGH #globalhealth #TNLF

Rest in peace to Chuck Norris Throwback to the one day the nurses thought I was cool when the Texas Ranger quoted me in a post on alcohol: creators.com/read/c-force/0…

🔥 HOT TOPIC 📘 @HepCommJournal Blood-based biomarker screening represents a transformative advance in liver cancer surveillance, and this #HCC Early Detection Strategy (HEDS) study tackles the crucial challenges of optimizing test thresholds and interpreting how changes over time affect early detection performance. Read the full study here: bit.ly/4bBmDFX

Blue Cross is actually a great partner in improving the quality of care that we provide I don’t blame any company for negotiating, but sending out letters to patients talking smack, that’s odd We have work to do and this is just to weird

Big win: Evidence-based vaccine policy matters. A new court ruling preserves hepatitis A & B recommendations and protects patients, scientific research, and liver & public health. AASLD remains committed to advocacy that drives impact. Learn more: aasld.org/policy-communi….

Nothing good will come from the transition to Cerner from CPRS I am sorry to say

Azacytidine, our fantastic hypomethylating agent, used for treatment of MDS and AML, was discovered in 1964, and then fell into oblivion. Almost 40 years later it was FDA approved as the first effective MDS treatment. A 🧵about an unusual revival:

3 rules for #colorectalcancer prevention from @UCLAHealth Medically Speaking podcast w/ Dr. Eve Glazier, @drfolamay & @katiecouric: 1️⃣Know your family history 2️⃣Screen at 45 (40 if high-risk) 3️⃣Don’t ignore persistent GI symptoms Early detection starts w/ a simple conversation.

Pro-tip for all the residents and fellows out there: bring the nurse/tech/staff who does the lactulose enema for your patient their favorite beverage from the local coffee shop.

I sat next to @scottisaacsmd yesterday and told him this episode was great

Co-Editors @ebtapper and Carmen Chak-Lui Wong share exciting science from the February issue of @HepCommJournal including studies on the reproductive hormones and #MASLD, increases in patient quality of life on #Resmetirom, the role of cGAS beyond viral DNA sensing, new #HCC research, and much more. #LiverTwitter Watch below and view the latest issue here: bit.ly/4sf5gBm youtube.com/watch?v=WYDtqX…

▶️ A #ColorectalCancerAwarenessMonth message from ACG President Dr. William Chey (@umfoodoc): 🔹 45 or older & average risk? 🔹 Family history of CRC? 🔹 Bowel symptoms? Talk to your doctor about getting screened. Your future self will thank you. ➡️ gi.org/coloncancer

📑 Prevalence and outcomes of steatotic liver disease subtypes in older adults❕ journals.lww.com/hepcomm/fullte…

Launching a new tradition in honor of an all-time great ... unmc.edu/newsroom/2026/…

📑 Electronic decision aids enhance management of primary care patients with steatotic liver disease‼️ ➡️ Automated, FIB-4–based guidance   ➡️ Guideline adherence ⬆️ from 30% to 46%    One click closer to improved #MASLD care❕ journals.lww.com/hepcomm/fullte…

AI didn’t help with endoscopy for gastric cancer detection (High rate of intestinal metaplasia in th population, 7 minute procedures)

Alpha-1 antitrypsin deficiency accelerates the progression of liver diseases Diabetes/obesity + ZZ = bad Not clearly the case with MZ The goal is risk factor modification

The rate, predictors, and outcomes of recompensation in MASH cirrhosis @HepCommJournal journals.lww.com/hepcomm/fullte…

@md_myer @PulmCrit @pgholam As you know, I agree. But these are vibes. And the meta-analysis combines very heterogenous populations. Given the pd/pk of ceft, long course inappropriate (I am hoping the NL will fund a trial of short course under consideration). Unlikely to benefit child A.

@PulmCrit @ebtapper @pgholam

Antibiotics probably aren’t beneficial for patients with cirrhosis & GI bleeding It will take time to change practice on this, but this is probably ripe for some antimicrobial stewardship The idea that a few doses of ceftriaxone improve *mortality* in GI bleed was always sus…

@Bubu_Banini @jlouissaint89 @LorenLaine2 @YaleMed @YNHH ❤️

From a grateful patient today. Just made my week! 😊😊😊 💕